MEDDDICAL has officially launched a new, comprehensive RWE advisory service catering to the rapidly evolving needs of biotech companies in 2026.
-- MEDDDICAL has announced the launch of a real-world evidence (RWE) advisory service for pharmaceutical and biotech teams seeking clearer data strategy, predictive intelligence, and market access support during increasingly compressed development cycles.
More information is available at https://medddical.com/services/
The service is designed for teams working across claims data strategy, synthetic patient cohort evaluation, AI-powered analytics, and RWE-informed market access planning, helping companies decide which data sources, analytical frameworks, and evidence-generation approaches are credible enough to support development, payer, and regulatory decisions.
The launch comes as AI-assisted drug discovery continues to compress early research timelines. In “Accelerating Drug Development with AI in the U.S. Pharmaceutical Industry,” Intuition Labs cites the Exscientia and Sumitomo Dainippon Pharma DSP-1181 program, where an AI-designed OCD drug candidate entered clinical trials after 12 months, compared with the usual five years. Pharmaphorum also reported on January 30, 2020, that the program identified a candidate from roughly 350 synthesized compounds, compared with a typical 2,500.
The ongoing evolution of AI-assisted tools has had impacts on every aspect of the clinical development timeline, from patient selection to iterative chemistry and beyond, according to the 2024 NIH-indexed review “Artificial Intelligence (AI) Applications in Drug Discovery and Drug Development.” However, this accelerated pace has brought with it new challenges. Fortrea’s November 27, 2025, article, “Six challenges facing emerging biotechs and how to solve them,” identifies regulatory complexity, clinical risk, access to capital, vendor management, multinational trial management, and visibility as key issues for emerging biotech companies.
Those challenges can become more pronounced when biotech companies run up against a regulatory landscape still adapting to AI-assisted development timelines. A recent Pharmaceutical Technology article points to federal-level regulatory uncertainty in the US and outdated guidance as points of concern. In that coverage, Dr. Rachel Salzman, CEO of Armatus Bio, discussed how uncertainty may influence where biotech companies and researchers choose to advance development work.
This pressure is underscored by a growing demand for RWE at all stages of development, particularly at the inception of a new project. Dr. David C. Klonoff of the Diabetes Research Institute has written that wearable devices and smartphones generate billions of user-specific data points every day, while AI can help researchers process large-scale real-world data and derive higher-quality evidence from it at an increased pace.
These findings could bring about a significant shift in how biotech projects are researched, funded, and progressed to market. In the meantime, emerging industry voices like MEDDDICAL will continue to help guide the future of RWE adoption.
“AI can accelerate discovery, but faster timelines only increase the need for stronger evidence strategy,” a MEDDDICAL spokesperson said. “Our advisory service helps pharma and biotech teams evaluate RWE options early, avoid poor data-fit decisions, and build evidence plans that can support development, access, and commercial strategy.”
About MEDDDICAL
MEDDDICAL is a comprehensive RWE advisory service operating at the intersection of intelligent technology and clinical best practices. Leaning on 13 years of industry experience, the advisory advocates for RWE strategies that orient client businesses toward the future of data collection and analysis.
Additional details can be found at https://medddical.com/
Contact Info:
Name: Rainer Muller
Email: Send Email
Organization: MEDDDICAL
Address: Aptos 221 Edificio D2C, Sotogrande, Cadiz 11310, Spain
Website: https://medddical.com
Source: NewsNetwork
Release ID: 89198268
In the event of any inaccuracies, problems, or queries arising from the content shared in this press release, we encourage you to notify us immediately at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our diligent team will be readily available to respond and take swift action within 8 hours to rectify any identified issues or assist with removal requests. Ensuring the provision of high-quality and precise information is paramount to us.